Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. XTL Biopharmaceuticals's Total Liabilities for the quarter that ended in Dec. 2025 was $0.42 Mil. XTL Biopharmaceuticals's Total Assets for the quarter that ended in Dec. 2025 was $0.17 Mil.
Therefore, XTL Biopharmaceuticals's Liabilities-to-Assets Ratio for the quarter that ended in Dec. 2025 was 2.53.
Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.
XTL Biopharmaceuticals Liabilities-to-Assets Related Terms
XTL Biopharmaceuticals Liabilities-to-Assets Historical Data
* Premium members only.
The historical data trend for XTL Biopharmaceuticals's Liabilities-to-Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XTLB vs VRTX, REGN, RVMD: Liabilities-to-Assets Comparison
For the Biotechnology subindustry, XTL Biopharmaceuticals's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
XTL Biopharmaceuticals Liabilities-to-Assets vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, XTL Biopharmaceuticals's Liabilities-to-Assets distribution charts can be found below:
* The bar in red indicates where XTL Biopharmaceuticals's Liabilities-to-Assets falls into.
Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.
XTL Biopharmaceuticals's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2025 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XTL Biopharmaceuticals (XTLB) has a Liabilities-to-Assets of 2.53 as of Dec. 2025. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on XTL Biopharmaceuticals and its competitors.
Is XTL Biopharmaceuticals' Liabilities-to-Assets too high?
XTL Biopharmaceuticals' current Liabilities-to-Assets is 2.53. Overall, XTL Biopharmaceuticals has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does XTL Biopharmaceuticals' Liabilities-to-Assets compare to VRTX and REGN?
XTL Biopharmaceuticals' Liabilities-to-Assets of 2.53 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Liabilities-to-Assets for a Biotechnology company?
A good Liabilities-to-Assets depends on the Biotechnology industry context. However, Liabilities-to-Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Liabilities-to-Assets mean?
A high Liabilities-to-Assets can signal that a stock is expensive relative to its fundamentals. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on XTL Biopharmaceuticals and its competitors. XTL Biopharmaceuticals's current Liabilities-to-Assets is 2.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is XTL Biopharmaceuticals stock overvalued right now?
XTL Biopharmaceuticals (XTLB) has a current Liabilities-to-Assets of 2.53. The current Liabilities-to-Assets is 2.53. XTL Biopharmaceuticals' overall GF Score™ is 26/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Liabilities-to-Assets calculated?
Liabilities-to-Assets is calculated from a company's financial statements. For XTL Biopharmaceuticals (XTLB), the current Liabilities-to-Assets is 2.53 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
XTL Biopharmaceuticals Ltd is engaged in the development of therapeutics for the treatment of unmet medical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE) and Sjogren's syndrome. hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with multiple myeloma (MM). rHuEPO is used in clinical practice for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia.
26GF Score
Get the complete analysis for XTLB
Liabilities-to-Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTLB has been successfully added to your 
